


2014 ● — **Encoded** founded by **Kartik Ramamoorthi** and **Stephanie Tagliatela**


- — Developed foundation for **genomics-based platform** technology

2015 ● — Established preclinical proof of concept data for targeting GABAergic inhibitory neurons


2018 ● — Achieved preclinical data to support our first clinical development program in Dravet syndrome


2019 ● — Presented proof of concept data in Dravet syndrome mouse model

 **46 employees**


 American Society of Gene + Cell Therapy


2020 ● — FDA granted Orphan drug and rare pediatric disease designation to Encoded's investigational gene therapy for Dravet syndrome

 **98 employees**




- — Initiated DRAVET ENGAGE with our first Caregiver Advisor Group Meeting

 **120 employees**




2021 ● — Published DRAVET ENGAGE findings in *Epilepsy & Behavior*

- — Presented initial ENVISION data at the American Epilepsy Society (AES) 2021 Annual Meeting



2022 ● — Published new systematic literature review in *Epilepsy & Behavior* of the burden of Dravet syndrome

 **180 employees**

- — Anticipate treating the first participant with ETX101 in our first-in-human clinical trial, ENDEAVOR, in 2022

